Altre lingue Achilles Therapeutics plc

Azioni

ACHL

US00449L1026

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,76 ^USD	-1,86%		-2,93%	-14,51%

05/04	ACHILLES THERAPEUTICS PLC : Chardan Research ribadisce il giudizio positivo sul titolo	ZM
05/04	ACHILLES THERAPEUTICS PLC : per Piper Sandler non è più Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ADRs Close Lower; Moatable Inc. Declines 33.3%	04/04
Syncona notes investee Achilles's annual loss narrows	04/04
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights	04/04
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	04/04
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04/04
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	04/04
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	04/04
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference	05/02
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction	18/12
Syncona notes investee company's quarterly loss	14/11
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights	13/11
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	22/09/23
Syncona's portfolio Achilles Therapeutics net loss narrows	04/08/23
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	04/08/23
Achilles Therapeutics : Corporate Presentation – August 2023	04/08/23
Achilles Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/08/23
Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	29/06/23
IO Summit EU 2023 - Personalised Neoantigen Therapies: State of the Art Neoantigen Immunogenicity Prediction	22/06/23
Achilles Therapeutics : SAE Cell and Gene Therapy 2023 - Targeting Clonal Neoantigens in Cancer	22/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Achilles Therapeutics plc

Azioni

ACHL

US00449L1026

Altre lingue

Filtri